IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 26,871.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,996 shares of the medical research company’s stock after acquiring an additional 40,844 shares during the quarter. International Assets Investment Management LLC’s holdings in IQVIA were worth $9,715,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA during the 3rd quarter worth $28,000. Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA during the 2nd quarter worth $29,000. Finally, Covestor Ltd raised its stake in shares of IQVIA by 45.3% during the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after buying an additional 48 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.1 %

IQV opened at $216.04 on Thursday. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The stock has a market capitalization of $39.38 billion, a price-to-earnings ratio of 28.06, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49. The business has a 50-day moving average of $235.88 and a two-hundred day moving average of $230.06. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on IQV shares. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and cut their price target for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Wednesday. UBS Group lifted their price target on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Evercore ISI cut their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, JPMorgan Chase & Co. cut their target price on shares of IQVIA from $288.00 to $279.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $267.27.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.